CXCL13 and CCL11 serum levels and lymphoma and disease activity in primary Sjögren's syndrome

Arthritis and Rheumatology

Volumn 67, Issue 12, 2015, Pages 3226-3233

  Nocturne, G ^a   Seror, R ^a   Fogel, O ^a   Belkhir, R ^b   Boudaoud, S ^a   Saraux, A ^c   Larroche, C ^d   Le Guern, V ^e   Gottenberg, J E ^f   Mariette, X ^a  

^a UNIVERSITÉ PARIS SACLAY   (France)

^b BICÊTRE HOSPITAL   (France)

^c BREST UNIVERSITY HOSPITAL   (France)

^d AVICENNE HOSPITAL   (France)

^e Institut Cochin   (France)

^f HÔPITAL DE HAUTEPIERRE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

B CELL ACTIVATING FACTOR; BIOLOGICAL MARKER; CHEMOKINE; CXCL13 CHEMOKINE; EOTAXIN; RHEUMATOID FACTOR; CCL11 PROTEIN, HUMAN; COMPLEMENT COMPONENT C4; CXCL13 PROTEIN, HUMAN; TNFSF13B PROTEIN, HUMAN;

ADULT; AGED; ARTICLE; ASSAY; B LYMPHOCYTE; B LYMPHOCYTE ACTIVATION; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE ASSOCIATION; FEMALE; HUMAN; LIGHT CHAIN; MAJOR CLINICAL STUDY; MALE; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; SJOEGREN SYNDROME; CLINICAL TRIAL; IMMUNOLOGY; LYMPHOCYTE ACTIVATION; MIDDLE AGED; MULTICENTER STUDY; MULTIVARIATE ANALYSIS; PROSPECTIVE STUDY; RISK FACTOR; SEVERITY OF ILLNESS INDEX;

AGED; B-CELL ACTIVATING FACTOR; B-LYMPHOCYTES; BIOMARKERS; CHEMOKINE CCL11; CHEMOKINE CXCL13; COHORT STUDIES; COMPLEMENT C4; FEMALE; HUMANS; LYMPHOCYTE ACTIVATION; LYMPHOMA, NON-HODGKIN; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROSPECTIVE STUDIES; RISK FACTORS; SEVERITY OF ILLNESS INDEX; SJOGREN'S SYNDROME;

EID: 84948417390     PISSN: 23265191     EISSN: 23265205     Source Type: Journal    
DOI: 10.1002/art.39315     Document Type: Article

References (35)

1. Moutsopoulos HM., Sjögren's syndrome: autoimmune epitheliitis. Clin Immunol Immunopathol 1994; 72: 162-5.
2. Nocturne G, Mariette X., Sjögren syndrome-associated lymphomas: an update on pathogenesis and management. Br J Haematol 2015; 168: 317-27.
3. Risselada AP, Kruize AA, Goldschmeding R, Lafeber FP, Bijlsma JW, van Roon JA., The prognostic value of routinely performed minor salivary gland assessments in primary Sjögren's syndrome. Ann Rheum Dis 2014; 73: 1537-40.
4. Theander E, Vasaitis L, Baecklund E, Nordmark G, Warfvinge G, Liedholm R, et al., Lymphoid organisation in labial salivary gland biopsies is a possible predictor for the development of malignant lymphoma in primary Sjögren's syndrome. Ann Rheum Dis 2011; 70: 1363-8.
5. Salomonsson S, Jonsson MV, Skarstein K, Brokstad KA, Hjelmstrom P, Wahren-Herlenius M, et al., Cellular basis of ectopic germinal center formation and autoantibody production in the target organ of patients with Sjögren's syndrome. Arthritis Rheum 2003; 48: 3187-201.
6. Nocturne G, Mariette X., Advances in understanding the pathogenesis of primary Sjögren's syndrome. Nat Rev Rheumatol 2013; 9: 544-56.
7. Reksten TR, Johnsen SJ, Jonsson MV, Omdal R, Brun JG, Theander E, et al., Genetic associations to germinal centre formation in primary Sjögren's syndrome. Ann Rheum Dis 2014; 73: 1253-8.
8. Purdue MP, Hofmann JN, Kemp TJ, Chaturvedi AK, Lan Q, Park JH, et al., A prospective study of 67 serum immune and inflammation markers and risk of non-Hodgkin lymphoma. Blood 2013; 122: 951-7.
9. 2-microglobulin and free light chains of immunoglobulins are associated with systemic disease activity in primary Sjögren's syndrome: data at enrollment in the prospective ASSESS cohort. PLoS One 2013; 8: e59868.
10. Vitali C, Bombardieri S, Jonsson R, Moutsopoulos HM, Alexander EL, Carsons SE, et al, and the European Study Group on Classification Criteria for Sjögren's Syndrome. Classification criteria for Sjögren's syndrome: a revised version of the European criteria proposed by the American-European Consensus Group. Ann Rheum Dis 2002; 61: 554-8.
11. Champey J, Corruble E, Gottenberg JE, Buhl C, Meyer T, Caudmont C, et al., Quality of life and psychological status in patients with primary Sjögren's syndrome and sicca symptoms without autoimmune features. Arthritis Rheum 2006; 55: 451-7.
12. Seror R, Ravaud P, Bowman SJ, Baron G, Tzioufas A, Theander E, et al, on behalf of the EULAR Sjögren's Task Force. EULAR Sjögren's Syndrome Disease Activity Index: development of a consensus systemic disease activity index for primary Sjögren's syndrome. Ann Rheum Dis 2010; 69: 1103-9.
13. Seror R, Bootsma H, Saraux A, Bowman SJ, Theander E, Brun JG, et al, on behalf of the EULAR Sjögren's Task Force. Defining disease activity states and clinically meaningful improvement in primary Sjögren's syndrome with EULAR primary Sjögren's syndrome disease activity (ESSDAI) and patient-reported indexes (ESSPRI). Ann Rheum Dis 2014. E-pub ahead of print.
14. Meiners P, Mariette X, Baron G, Vitali C, Bowman S, Gottenberg JE, et al., Développement d'un score ClinESSDAI (EULAR Sjögren's Syndrome Disease Activity Index) sans domaine biologique: un outil pour les études biologiques. In: Proceedings of the 27th Congress of the French Society of Rheumatology; 2014 Dec 7-9; Paris, France. p. 49.
15. Lessard CJ, Li H, Adrianto I, Ice JA, Rasmussen A, Grundahl KM, et al., Variants at multiple loci implicated in both innate and adaptive immune responses are associated with Sjögren's syndrome. Nat Genet 2013; 45: 1284-92.
16. Amft N, Curnow SJ, Scheel-Toellner D, Devadas A, Oates J, Crocker J, et al., Ectopic expression of the B cell-attracting chemokine BCA-1 (CXCL13) on endothelial cells and within lymphoid follicles contributes to the establishment of germinal center-like structures in Sjögren's syndrome. Arthritis Rheum 2001; 44: 2633-41.
17. Rosengren S, Wei N, Kalunian KC, Kavanaugh A, Boyle DL., CXCL13: a novel biomarker of B-cell return following rituximab treatment and synovitis in patients with rheumatoid arthritis. Rheumatology (Oxford) 2013; 50: 603-10.
18. Kramer JM, Klimatcheva E, Rothstein TL., CXCL13 is elevated in Sjögren's syndrome in mice and humans and is implicated in disease pathogenesis. J Leukoc Biol 2013; 94: 1079-89.
19. Forster R, Mattis AE, Kremmer E, Wolf E, Brem G, Lipp M., A putative chemokine receptor, BLR1, directs B cell migration to defined lymphoid organs and specific anatomic compartments of the spleen. Cell 1996; 87: 1037-47.
20. Luther SA, Lopez T, Bai W, Hanahan D, Cyster JG., BLC expression in pancreatic islets causes B cell recruitment and lymphotoxin-dependent lymphoid neogenesis. Immunity 2000; 12: 471-81.
21. Greisen S, Schelde K, Rasmussen T, Kragstrup T, Stengaard-Pedersen K, Hetland M, et al., CXCL13 predicts disease activity in early rheumatoid arthritis and could be an indicator of the therapeutic 'window of opportunity.' Arthritis Res Ther 2014; 16: 434.
22. Sellam J, Rouanet S, Hendel-Chavez H, Miceli-Richard C, Combe B, Sibilia J, et al., CCL19, a B cell chemokine, is related to the decrease of blood memory B cells and predicts the clinical response to rituximab in patients with rheumatoid arthritis. Arthritis Rheum 2013; 65: 2253-61.
23. Schiffer L, Worthmann K, Haller H, Schiffer M., CXCL13 as a new biomarker of systemic lupus erythematosus and lupus nephritis: from bench to bedside? Clin Exp Immunol 2014; 179: 85-9.
24. Barone F, Bombardieri M, Rosado MM, Morgan PR, Challacombe SJ, De Vita S, et al., CXCL13, CCL21, and CXCL12 expression in salivary glands of patients with Sjögren's syndrome and MALT lymphoma: association with reactive and malignant areas of lymphoid organization. J Immunol 2008; 180: 5130-40.
25. Pitzalis C, Jones GW, Bombardieri M, Jones SA., Ectopic lymphoid-like structures in infection, cancer and autoimmunity. Nat Rev Immunol 2014; 14: 447-62.
26. Mariette X., Lymphomas complicating Sjögren's syndrome and hepatitis C virus infection may share a common pathogenesis: chronic stimulation of rheumatoid factor B cells. Ann Rheum Dis 2001; 60: 1007-10.
27. Syversen SW, Goll GL, Haavardsholm EA, Boyesen P, Lea T, Kvien TK., A high serum level of eotaxin (CCL 11) is associated with less radiographic progression in early rheumatoid arthritis patients. Arthritis Res Ther 2008; 10: R28.
28. Deshmukh US, Nandula SR, Thimmalapura PR, Scindia YM, Bagavant H., Activation of innate immune responses through Toll-like receptor 3 causes a rapid loss of salivary gland function. J Oral Pathol Med 2009; 38: 42-7.
29. Szodoray P, Alex P, Jonsson MV, Knowlton N, Dozmorov I, Nakken B, et al., Distinct profiles of Sjögren's syndrome patients with ectopic salivary gland germinal centers revealed by serum cytokines and BAFF. Clin Immunol 2005; 117: 168-76.
30. Reksten TR, Jonsson MV, Szyszko EA, Brun JG, Jonsson R, Brokstad KA., Cytokine and autoantibody profiling related to histopathological features in primary Sjögren's syndrome. Rheumatology (Oxford) 2009; 48: 1102-6.
31. Elsner J, Escher SE, Forssmann U., Chemokine receptor antagonists: a novel therapeutic approach in allergic diseases. Allergy 2004; 59: 1243-58.
32. Delaleu N, Mydel P, Kwee I, Brun JG, Jonsson MV, Jonsson R., High fidelity between saliva proteomics and the biologic state of salivary glands defines biomarker signatures for primary Sjögren's syndrome. Arthritis Rheumatol 2015; 67: 1084-95.
33. Jinquan T, Jacobi HH, Jing C, Millner A, Sten E, Hviid L, et al., CCR3 expression induced by IL-2 and IL-4 functioning as a death receptor for B cells. J Immunol 2003; 171: 1722-31.
34. Requena P, Campo JJ, Umbers AJ, Ome M, Wangnapi R, Barrios D, et al., Pregnancy and malaria exposure are associated with changes in the B cell pool and in plasma eotaxin levels. J Immunol 2014; 193: 2971-83.
35. Brito Zeron P, Kostov B, Solans R, de Luna G, Casanovas A, Diaz-Lopez B, et al., Association between systemic activity and lymphoma in primary Sjögren syndrome: baseline ESSDAI predictors in 921 Spanish patients (GEAS-SS Registry) [abstract]. Ann Rheum Dis 2014; 73 Suppl 2: 142.